Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | SLC19A2 | O60779 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SREBF2 | Q12772 | 5/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27592765 | 0.89 | KDM4E (0.42) | KDM4ELMNACYP3A4TSHRNOS2 | |
| Ammonia Solution, Strong SCHEMBL27648732 | 0.88 | KDM4E (0.41) | KDM4ELMNACYP3A4TSHRNOS2 | |
| SCHEMBL830187 | 0.85 | CYP1A2 (0.37) | NOS2CYP1A2POLBSREBF2MAP4K4 | |
| SCHEMBL16815708 | 0.84 | KDM4E (0.39) | KDM4ELMNACYP3A4TSHRNOS2 | |
| SCHEMBL20108955 | 0.84 | TLR8 (0.36) | KDM4ELMNACYP3A4TSHRNOS2 | |
| Ammonia Solution, Strong SCHEMBL28652832 | 0.83 | CYP1A2 (0.36) | NOS2CYP1A2POLBSREBF2MAP4K4 | |
| SCHEMBL12313633 | 0.82 | NOS3 (0.30) | NOS2NOS3NOS1 | |
| Ammonia Solution, Strong SCHEMBL11451734 | 0.81 | CYP1A2 (0.35) | NOS2CYP1A2POLBSREBF2MAP4K4 | |
| SCHEMBL14234022 | 0.80 | KCNH2 (0.41) | KDM4ELMNACYP3A4TSHRNOS2 | |
| SCHEMBL20110031 | 0.80 | CHRNB2 (0.31) | CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2016-07-07 | — | — | US | disclosed |
| US-9079918-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140343276-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-20 | — | — | US | disclosed |
| CN-1039645-C | 1,3-(substd. thio) acetoxy Melbamycinum derivatives, their preparation method, and use in agricultural chemistry | SANKYO CO (JP) | 1998-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343276-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | KDM4E 796/4885LMNA 1757/4885CYP3A4 1109/4885 |
| US-20160194303-A1 | HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | ICOS, NFATC1, CD74 | KDM4E 1996/4885LMNA 4845/4885CYP3A4 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.